Kovina Therapeutics Announces Publication in PNAS Validating HPV E6 Targeted Therapeutic Approach
Kovina Therapeutics Inc. today announced publication in the Proceedings of the National Academy of Sciences (PNAS) of research validating its HPV E6 targeted therapeutic approach.
Kovina Therapeutics Receives NIH Grant to Develop Human Papillomavirus E6 Inhibitors to Treat Oropharyngeal Cancers
Kovina Therapeutics Inc. announced receipt of a Small Business Innovation Research (SBIR) one-year Phase I award from the National Institute of Dental and Craniofacial Research (NIDCR/NIH) to treat oropharyngeal cancers caused by Human Papillomavirus (HPV) infections. The award provides approximately $275,000 with the opportunity for advancement to Phase 2.
Kovina Therapeutics Receives Grant from NIH to Advance Human Papillomavirus Premalignant Infection Treatments
Kovina Therapeutics Inc. announced receipt of a Small Business Innovation Research (SBIR) one-year Phase I award from the National Institute of Allergy and Infectious Diseases (NIAID)/NIH to treat Human Papillomavirus (HPV) premalignant infections. The award provides approximately $300,000 with the opportunity for advancement to Phase 2.
Kovina Therapeutics Receives National Cancer Institute Grant to Advance Human Papillomavirus Cancer Treatment
Kovina Therapeutics Inc. announced receipt of a Fast-Track Small Business Technology Transfer (STTR) grant from the National Cancer Institute/NIH. With successful achievement of its milestones, the award will transition to a Small Business Innovation Research (SBIR) award and will provide approximately $2,400,000 over three years.
